Independent pricing breakdown · May 2026
Quick answer
Wegovy costs about $1,349 per month at retail pharmacies in 2026. With insurance coverage, most patients pay $0–$25 per month after copay. Without insurance, Novo Nordisk's direct cash-pay program offers Wegovy at $349 per month. Compounded semaglutide — the same active ingredient — is available through telehealth providers from $99 per month.
Sorted by source. Average list pricing for a standard 30-day supply at typical dose.
| Source | Monthly cost | Note |
|---|---|---|
| Retail pharmacy (no insurance) | $1,349/month | Average list price across major US pharmacies in 2026 |
| With commercial insurance + copay card | $0–$25/month | Most insured patients with Novo's WegovyOne savings card |
| Manufacturer direct cash-pay (NovoCare) | $349/month | Self-pay program launched 2024, expanded 2026 |
| Compounded semaglutide via telehealth | From $99/month | Through licensed 503A pharmacy partners |
| Compounded 6-month plan first-order | From $875 total | Effective ~$146/month with new-patient discount |
Wegovy uses semaglutide — the same active ingredient as Ozempic — but is dosed higher and FDA-approved specifically for chronic weight management. The pricing reflects manufacturer R&D recovery, the 2.4 mg therapeutic dose ceiling, and the absence of generic competition.
Novo Nordisk holds a US patent on semaglutide that does not expire until late 2032, which means no generic Wegovy will reach the market for at least six more years. Compounded semaglutide is the only legal lower-cost alternative until then.
Insurance coverage of Wegovy varies dramatically by plan type. Roughly 30% of large-employer plans covered Wegovy for weight management in 2024; that number dropped to about 18% by April 2026 after several major carriers pulled coverage citing trajectory cost.
Patients with coverage typically pay a $0–$25 copay after using the Novo Nordisk WegovyOne savings card. Patients on plans without weight-management coverage usually pay full retail unless they qualify under a comorbidity pathway.
Medicare Part D plans cannot cover weight-loss drugs by statute, though the 2026 Medicare Bridge pilot is testing limited reimbursement for select beneficiaries.
Three pathways move the price below retail. The Novo Nordisk direct cash-pay program at $349 per month is the cheapest brand-name path. Manufacturer copay cards reduce insured patients to $0–$25. Switching to compounded semaglutide through a licensed telehealth provider drops effective monthly cost to $99–$200.
Compounded semaglutide is not the same product as Wegovy, but it contains the same active ingredient prepared in a 503A licensed pharmacy under provider supervision. Quality varies across providers — only use a program that uses LegitScript-certified pharmacies.
Top-rated telehealth providers offering compounded equivalents to brand-name medications. Sorted by editorial rating.
Comprehensive GLP-1 programs with board-certified physicians and lab monitoring
Excellent
Highest-converting GLP-1 provider — $16 EPC, personalized consultations, tailored prescriptions
Excellent
Fastest-growing GLP-1 provider — oral, sublingual, and injectable options with Affirm financing
Excellent
150K+ members with 5 medication forms — injections, oral drops, lozenges, tablets, and pills
Very Good
Without insurance, Wegovy costs about $1,349 per month at retail pharmacies in 2026. The Novo Nordisk direct cash-pay program offers it at $349 per month. Compounded semaglutide — the same active ingredient — is available from telehealth providers starting at $99 per month.
No. Medicare Part D is prohibited by statute from covering weight-loss medications. The 2026 Medicare Bridge pilot is testing limited coverage for select beneficiaries, but most Medicare patients pay cash or use compounded alternatives.
Compounded semaglutide contains the same active ingredient as Wegovy. Effectiveness depends on dose and adherence, which are provider-determined. Compounded versions are not FDA-approved as finished drugs but are produced from FDA-regulated active ingredients in 503A licensed pharmacies.
Novo Nordisk's direct cash-pay program at $349 per month, as of 2026. The program is available to US patients without requiring insurance and ships through Express Scripts pharmacy partners.